Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 - Concepedia

Concepedia

Publication | Open Access

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

DOI Full Paper Access

712

Citations

21

References

2011

Year

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, Nancy E. Davidson, Charles E. Geyer, Silvana Martino, Eleftherios P. Mamounas, Peter A. Kaufman, Norman Wolmark

Journal of Clinical Oncology

Abstract

These data demonstrate consistent DFS and OS advantages of adjuvant trastuzumab over time, with the longest follow-up reported to date. The clinical benefits continue to outweigh the risks of adverse effects.

References

	Year	Citations

Page 1